- Supply chain disruptions due to reliance on raw materials from Mainland China.
- Long timelines for product launch and high risks before product launch.
- Competition from large international pharmaceutical companies.
Phytohealth Corporation
Greenhouse gas emissions & sustainability report data
In its 2023 reporting, Phytohealth Corporation disclosed greenhouse gas emissions of 1.4K tCO2e/year (Scope 1 and 2 combined). By scope: Scope 1: 114.71 tCO2e/year; Scope 2: 1.3K tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
1.4K tCO2e/year (Scope 1 and 2 combined)
2023
Water Usage
20.2K m3/year
2023
Waste
5.50 tons/year
2023
📊 Emissions by Scope (2023)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 1 | Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions). | 114.71 tCO2e/year |
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 1.3K tCO2e/year |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
✅ Reported Environmental Achievements
- Reduced waste generation by 8.33%
- Reduced water consumption by 5.72%
🎯 Climate & Sustainability Targets
🔜 Short-term
- Launch Oraphine®60mg soft Capsule for sale
- Seek sales partners in the European Union and Southeast Asia for Oraphine®60mg soft Capsule
📅 Medium-term
- Expand applications of PG2 Lyo. Injection 500mg to different types and stages of cancer
- Successfully develop and launch new drug research and development products/technologies.
🔭 Long-term
- Continuously expanding/developing other indications for PG2 Lyo. Injection 500mg
- Collaborating with international pharmaceutical companies to develop new drug research and development products/technologies.
🌱 ESG Focus Areas
Environmental ProtectionEmployee WelfareEthical Corporate Governance